Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma
Standard
Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma. / Eichenauer, Till; Shadanpour, Navid; Kluth, Martina; Göbel, Cosima; Weidemann, Sören; Fraune, Christoph; Büscheck, Franziska; Hube-Magg, Claudia; Möller-Koop, Christina; Dahlem, Roland; Fisch, Margit; Rink, Michael; Riechardt, Silke; Burandt, Eike; Bernreuther, Christian; Minner, Sarah; Simon, Ronald; Sauter, Guido; Wilczak, Waldemar; Clauditz, Till.
in: WORLD J SURG ONCOL, Jahrgang 18, Nr. 1, 13.06.2020, S. 128.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma
AU - Eichenauer, Till
AU - Shadanpour, Navid
AU - Kluth, Martina
AU - Göbel, Cosima
AU - Weidemann, Sören
AU - Fraune, Christoph
AU - Büscheck, Franziska
AU - Hube-Magg, Claudia
AU - Möller-Koop, Christina
AU - Dahlem, Roland
AU - Fisch, Margit
AU - Rink, Michael
AU - Riechardt, Silke
AU - Burandt, Eike
AU - Bernreuther, Christian
AU - Minner, Sarah
AU - Simon, Ronald
AU - Sauter, Guido
AU - Wilczak, Waldemar
AU - Clauditz, Till
PY - 2020/6/13
Y1 - 2020/6/13
N2 - BACKGROUND: Deletions of 17p13 recurrently occur in renal cell carcinoma (RCC) but their prognostic role seems to be uncertain.METHODS: To determine prevalence, relationship with tumor phenotype, and patient prognosis, a tissue microarray containing samples from 1809 RCCs was evaluated using dual labeling fluorescence in situ hybridization (FISH) with 17p13 and chromosome 17 centromere probes.RESULTS: A 17p13 deletion was found in 72 of 1429 interpretable tumors. The frequency of 17p13 deletions varied greatly between RCC subtypes and was highest in chromophobe RCC (24/72; 33.3%). 17p13 deletions were also found in 35 (3.7%) of 946 clear cell RCC, 9 (4.3%) of 208 papillary RCC, 1 of 121 oncocytomas (0.8%), as well as in several rare cases of comprising 1 of 7 Xp11.2 translocation cancers, 1 of 3 collecting duct carcinomas, and 1 of 20 not otherwise specified (NOS) carcinomas. In clear cell carcinomas, 17p13 deletions revealed a strong and consistent association with higher Fuhrman, ISUP, and Thoenes grade (p < 0.0001 each), and linked to advanced tumor stage (p = 0.0168), large tumor diameter (p = 0.0004), distant metastases (p = 0.0077), cancer-specific survival (p = 0.0391), and recurrence-free survival (p = 0.0072). In multivariate analysis, 17p13 deletions showed in clear cell RCC a dependent prognostic role for established clinical-pathological parameters.CONCLUSION: 17p13 deletions have a dual role in RCC. They are associated with disease progression in clear cell RCC and possibly other subtypes and they are linked to the development of chromophobe RCC-a subtype with a particularly favorable prognosis.
AB - BACKGROUND: Deletions of 17p13 recurrently occur in renal cell carcinoma (RCC) but their prognostic role seems to be uncertain.METHODS: To determine prevalence, relationship with tumor phenotype, and patient prognosis, a tissue microarray containing samples from 1809 RCCs was evaluated using dual labeling fluorescence in situ hybridization (FISH) with 17p13 and chromosome 17 centromere probes.RESULTS: A 17p13 deletion was found in 72 of 1429 interpretable tumors. The frequency of 17p13 deletions varied greatly between RCC subtypes and was highest in chromophobe RCC (24/72; 33.3%). 17p13 deletions were also found in 35 (3.7%) of 946 clear cell RCC, 9 (4.3%) of 208 papillary RCC, 1 of 121 oncocytomas (0.8%), as well as in several rare cases of comprising 1 of 7 Xp11.2 translocation cancers, 1 of 3 collecting duct carcinomas, and 1 of 20 not otherwise specified (NOS) carcinomas. In clear cell carcinomas, 17p13 deletions revealed a strong and consistent association with higher Fuhrman, ISUP, and Thoenes grade (p < 0.0001 each), and linked to advanced tumor stage (p = 0.0168), large tumor diameter (p = 0.0004), distant metastases (p = 0.0077), cancer-specific survival (p = 0.0391), and recurrence-free survival (p = 0.0072). In multivariate analysis, 17p13 deletions showed in clear cell RCC a dependent prognostic role for established clinical-pathological parameters.CONCLUSION: 17p13 deletions have a dual role in RCC. They are associated with disease progression in clear cell RCC and possibly other subtypes and they are linked to the development of chromophobe RCC-a subtype with a particularly favorable prognosis.
U2 - 10.1186/s12957-020-01902-y
DO - 10.1186/s12957-020-01902-y
M3 - SCORING: Journal article
C2 - 32534597
VL - 18
SP - 128
JO - WORLD J SURG ONCOL
JF - WORLD J SURG ONCOL
SN - 1477-7819
IS - 1
ER -